Unofficially Dangerous? Drug Side Effects Title: Supreme Court Rules against Zicam Maker Adam Liptak Author: Source: New York Times, March 23, 2011, http://www.nytimes.com/2011/03/23/ health/23bizcourt.html The Supreme Court unanimously ruled on Tuesday that investors suing a drug company for securities fraud may rely on its failure to disclose scattered reports of adverse affects [sic] from an over-the- counter cold remedy that fell short of statistical significance. The following is an extract from a New York Times article on Zicam: The case involved Zicam, a nasal spray and gel made by Matrixx Initiatives and sold as a homeopathic medicine. From 1999 to 2004, the plaintiffs said, the company received reports that the products very strong momentum" though, by the plaintiffs' calculations, Zicam accounted for about 70% of its sales. ght have caused some users to lose their sense of smell, a condition called anosmia. Matrixx did not disclose the reports and in 2003, the company said it was "poised for growth" and had In the case before the justices, Matrixx Initiatives Inc. v. Siracusano, No. 09-1156, lawyers for Matrixx argued that it should not have been required to disclose small numbers of unreliable reports, which were the only ones available in 2004, they said. They added that the company should face liability for securities fraud only if the reports had been collectively statistically significant. ... Questions 1. This is an unusual situation. Clearly identify (in your own well-chosen words) the two outcomes that are being compared when the words "statistically significant" are used. 2. What is Matrixx claiming? How is their claim related to a Type I Error Rate (false positive rate)?
Unofficially Dangerous? Drug Side Effects Title: Supreme Court Rules against Zicam Maker Adam Liptak Author: Source: New York Times, March 23, 2011, http://www.nytimes.com/2011/03/23/ health/23bizcourt.html The Supreme Court unanimously ruled on Tuesday that investors suing a drug company for securities fraud may rely on its failure to disclose scattered reports of adverse affects [sic] from an over-the- counter cold remedy that fell short of statistical significance. The following is an extract from a New York Times article on Zicam: The case involved Zicam, a nasal spray and gel made by Matrixx Initiatives and sold as a homeopathic medicine. From 1999 to 2004, the plaintiffs said, the company received reports that the products very strong momentum" though, by the plaintiffs' calculations, Zicam accounted for about 70% of its sales. ght have caused some users to lose their sense of smell, a condition called anosmia. Matrixx did not disclose the reports and in 2003, the company said it was "poised for growth" and had In the case before the justices, Matrixx Initiatives Inc. v. Siracusano, No. 09-1156, lawyers for Matrixx argued that it should not have been required to disclose small numbers of unreliable reports, which were the only ones available in 2004, they said. They added that the company should face liability for securities fraud only if the reports had been collectively statistically significant. ... Questions 1. This is an unusual situation. Clearly identify (in your own well-chosen words) the two outcomes that are being compared when the words "statistically significant" are used. 2. What is Matrixx claiming? How is their claim related to a Type I Error Rate (false positive rate)?
Chapter9: Sequences, Probability And Counting Theory
Section9.7: Probability
Problem 1SE: What term is used to express the likelihood of an event occurring? Are there restrictions on its...
Related questions
Topic Video
Question
Need the answer to question 1.
![Unofficially Dangerous?
Drug Side Effects
Title:
Supreme Court Rules against Zicam Maker
Adam Liptak
Author:
Source:
New York Times, March 23, 2011, http://www.nytimes.com/2011/03/23/
health/23bizcourt.html
The Supreme Court unanimously ruled on Tuesday that investors suing a drug company for securities
fraud may rely on its failure to disclose scattered reports of adverse affects [sic] from an over-the-
counter cold remedy that fell short of statistical significance.
The following is an extract from a New York Times article on Zicam:
The case involved Zicam, a nasal spray and gel made by Matrixx Initiatives and sold as a homeopathic
medicine. From 1999 to 2004, the plaintiffs said, the company received reports that the products
very strong momentum" though, by the plaintiffs' calculations, Zicam accounted for about 70% of its
sales.
ght have caused some users to lose their sense of smell, a condition called anosmia.
Matrixx did not disclose the reports and in 2003, the company said it was "poised for growth" and had
In the case before the justices, Matrixx Initiatives Inc. v. Siracusano, No. 09-1156, lawyers for Matrixx
argued that it should not have been required to disclose small numbers of unreliable reports, which
were the only ones available in 2004, they said. They added that the company should face liability
for securities fraud only if the reports had been collectively statistically significant.
...
Questions
1. This is an unusual situation. Clearly identify (in your own well-chosen words)
the two outcomes that are being compared when the words "statistically
significant" are used.
2. What is Matrixx claiming? How is their claim related to a Type I Error Rate
(false positive rate)?](/v2/_next/image?url=https%3A%2F%2Fcontent.bartleby.com%2Fqna-images%2Fquestion%2Fc2eed048-a1d0-4ec7-a36b-99788d12ae87%2Fb8260ee7-f985-42f0-993c-c4466fe50fee%2F9q1vrlc.jpeg&w=3840&q=75)
Transcribed Image Text:Unofficially Dangerous?
Drug Side Effects
Title:
Supreme Court Rules against Zicam Maker
Adam Liptak
Author:
Source:
New York Times, March 23, 2011, http://www.nytimes.com/2011/03/23/
health/23bizcourt.html
The Supreme Court unanimously ruled on Tuesday that investors suing a drug company for securities
fraud may rely on its failure to disclose scattered reports of adverse affects [sic] from an over-the-
counter cold remedy that fell short of statistical significance.
The following is an extract from a New York Times article on Zicam:
The case involved Zicam, a nasal spray and gel made by Matrixx Initiatives and sold as a homeopathic
medicine. From 1999 to 2004, the plaintiffs said, the company received reports that the products
very strong momentum" though, by the plaintiffs' calculations, Zicam accounted for about 70% of its
sales.
ght have caused some users to lose their sense of smell, a condition called anosmia.
Matrixx did not disclose the reports and in 2003, the company said it was "poised for growth" and had
In the case before the justices, Matrixx Initiatives Inc. v. Siracusano, No. 09-1156, lawyers for Matrixx
argued that it should not have been required to disclose small numbers of unreliable reports, which
were the only ones available in 2004, they said. They added that the company should face liability
for securities fraud only if the reports had been collectively statistically significant.
...
Questions
1. This is an unusual situation. Clearly identify (in your own well-chosen words)
the two outcomes that are being compared when the words "statistically
significant" are used.
2. What is Matrixx claiming? How is their claim related to a Type I Error Rate
(false positive rate)?
Expert Solution
This question has been solved!
Explore an expertly crafted, step-by-step solution for a thorough understanding of key concepts.
This is a popular solution!
Trending now
This is a popular solution!
Step by step
Solved in 2 steps
Knowledge Booster
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, statistics and related others by exploring similar questions and additional content below.Recommended textbooks for you
Glencoe Algebra 1, Student Edition, 9780079039897…
Algebra
ISBN:
9780079039897
Author:
Carter
Publisher:
McGraw Hill
Glencoe Algebra 1, Student Edition, 9780079039897…
Algebra
ISBN:
9780079039897
Author:
Carter
Publisher:
McGraw Hill